Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics develops investigational therapies for immune-mediated diseases, with news centered on its RASP modulator platform and late-stage ocular programs. Company updates commonly cover reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and next-generation RASP modulators including ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases.
Recurring developments include FDA interactions on the reproxalap New Drug Application, clinical and preclinical results, pipeline prioritization, manufacturing and regulatory disclosures, and research-and-development presentations. Aldeyra also reports conference participation and corporate updates tied to its Nasdaq-listed biotechnology issuer profile.
Aldeyra Therapeutics (Nasdaq: ALDX) reported significant progress in Q2 2022, with cash reserves of $196.7 million expected to support operations into 2023. Key upcoming milestones include pre-NDA meetings with the FDA for reproxalap, aimed at treating dry eye disease, and ADX-2191 for primary vitreoretinal lymphoma. Positive results from clinical trials of reproxalap indicated statistical superiority in reducing ocular discomfort. However, the company reported a net loss of $17.8 million for the quarter, an increase from the prior year, primarily due to rising R&D expenses.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a conference call on August 5, 2022, at 8:00 a.m. ET to discuss its financial results for Q2 2022, which ended June 30, 2022, along with recent corporate highlights. Domestic callers can dial (844) 200-6205 or (929) 526-1599 for international calls, using access code 908644. A live audio webcast will also be available on Aldeyra's website and will remain archived for 90 days. Aldeyra focuses on innovative therapies for immune-mediated diseases, with key products in development addressing various conditions.
Aldeyra Therapeutics (NASDAQ: ALDX) announced positive results from its crossover clinical trial of the investigational drug reproxalap for dry eye disease. The study achieved primary endpoints, demonstrating statistical superiority over a vehicle for both ocular redness (P=0.0004) and the Schirmer test (P=0.0005). Secondary endpoints also showed significant improvements in dryness, discomfort, grittiness, stinging, burning, and itching symptoms. No safety issues were reported, and the FDA meeting for a New Drug Application is scheduled for Q3 2022, with submission plans for reproxalap data following.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will conduct a webcast and conference call on July 12, 2022, at 8:00 a.m. ET to present top-line results from a crossover clinical trial of reproxalap, an investigational treatment for dry eye disease. The event will be accessible via dial-in or through a live audio webcast on Aldeyra's website. The trial aims to provide insights on the efficacy of reproxalap, which is in late-stage trials targeting immune-mediated diseases. Further details and archives will be available on their website.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced that Dr. Todd C. Brady, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 10, 2022, at 9:30 a.m. ET. The event will include a conversation with Dr. Kelly Shi, a Senior Research Analyst in Biotechnology. Investors can access the live webcast through Aldeyra's website, with a video replay available for 90 days afterwards. Aldeyra is focused on innovative therapies for immune-mediated diseases, including its lead candidates, reproxalap and ADX-629.
Aldeyra Therapeutics (ALDX) announced its achievement of the primary endpoint in the Phase 3 TRANQUILITY-2 clinical trial for reproxalap, a treatment for dry eye disease. The drug demonstrated statistical superiority in the Schirmer test (p=0.0001) and responder proportions (p0.0001) after a single dose. The company plans to submit a New Drug Application (NDA) encompassing results from five controlled trials, potentially representing the most comprehensive submission for dry eye disease. A Pre-NDA meeting with the FDA is anticipated in Q3 2022, with results from an ongoing safety trial expected soon.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a webcast and conference call on June 8, 2022, at 8:00 a.m. ET to discuss top-line results from its Phase 3 TRANQUILITY-2 Trial of reproxalap in treating dry eye disease. Interested participants can access the call via dial-in numbers or through a live audio webcast on Aldeyra's website. Following the event, a recording will be available on the site for 90 days. Aldeyra is focused on innovative therapies targeting immune-mediated diseases.
Aldeyra Therapeutics (NASDAQ: ALDX) announced Schirmer test designation as the primary endpoint in its Phase 3 TRANQUILITY-2 trial for reproxalap, targeting dry eye disease. This decision follows favorable post-hoc analyses from previous trials, indicating reproxalap’s statistically significant reduction in ocular redness. The company plans to use these results to support a New Drug Application (NDA) submission, pending ongoing safety trials. Results from TRANQUILITY-2 are expected in Q2 2022, highlighting the unmet need for quicker, non-steroidal treatment options in dry eye disease.
Aldeyra Therapeutics, a biotechnology company focused on immune-mediated diseases, announced that President and CEO Todd C. Brady will speak at the H.C. Wainwright Global Investment Conference. The fireside chat, featuring Vice President of Equity Research Matthew Caufield, will be available on demand starting 7:00 a.m. ET on May 24, 2022. Interested viewers can access the event through the Investors & Media section on Aldeyra's website, which will be archived for 90 days. Aldeyra's leading products include reproxalap and ADX-629, targeting immune-inflammation.
Aldeyra Therapeutics (ALDX) announced positive findings from a post-hoc analysis of the Phase 3 TRANQUILITY trial for reproxalap, indicating statistical superiority (p=0.020) in reducing ocular redness, the primary endpoint. This follows a similar confirmation in the Phase 2 trial (p=0.003). Aldeyra plans to engage with the FDA, including ocular redness as an objective sign in its upcoming New Drug Application (NDA) expected mid-2022, contingent on discussions and outcomes from the ongoing TRANQUILITY-2 trial.